LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

47.35 1.41

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

46.91

Massimo

49.06

Metriche Chiave
By Trading Economics
Entrata	-14M -130M
Vendite	-888K 143K
Margine di Profitto	-90,972.727
Dipendenti	437
EBITDA	33K -129M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+71.42% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	258M 4.3B
Apertura precedente	45.94
Chiusura precedente	47.35

Notizie sul Sentiment di mercato

By Acuity

26%

74%

52 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 dic 2025, 23:48 UTC

I principali Market Mover

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8 dic 2025, 23:44 UTC

Discorsi di Mercato

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8 dic 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8 dic 2025, 23:13 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 dic 2025, 23:13 UTC

Discorsi di Mercato

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8 dic 2025, 23:09 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8 dic 2025, 22:46 UTC

Discorsi di Mercato

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8 dic 2025, 22:01 UTC

Discorsi di Mercato

Miners Poised to Do Well in 2026 -- Market Talk

8 dic 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8 dic 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8 dic 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8 dic 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8 dic 2025, 21:51 UTC

Discorsi di Mercato

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8 dic 2025, 21:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

8 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 dic 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8 dic 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8 dic 2025, 21:36 UTC

Discorsi di Mercato

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8 dic 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8 dic 2025, 21:12 UTC

Acquisizioni, Fusioni, Takeovers

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 dic 2025, 21:08 UTC

Discorsi di Mercato

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8 dic 2025, 20:38 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8 dic 2025, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 dic 2025, 20:18 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8 dic 2025, 20:07 UTC

Discorsi di Mercato

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8 dic 2025, 20:06 UTC

Discorsi di Mercato

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8 dic 2025, 20:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 dic 2025, 20:05 UTC

Discorsi di Mercato

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8 dic 2025, 20:01 UTC

Discorsi di Mercato

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

71.42% in crescita

Previsioni per 12 mesi

Media 80 USD 71.42%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

52 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.